Key Highlights

  • Pulmatrix announced a definitive Reverse merger agreement with Eos SENOLYTIX on March 26, 2026, following the termination of an earlier Cullgen deal.
  • Under the terms, Eos Stakeholders would own roughly 94% of the combined company, with legacy Pulmatrix holders retaining about 6%.
  • The combined entity is expected to trade on Nasdaq as Eos SENOLYTIX, Inc. under the ticker 'EOSX,' pending exchange approval.

Pulmatrix has effectively transformed from an inhaled-therapies developer into a merger vehicle, and that shift is the real story for shareholders in 2026. Any short-term jump in trading interest in PULM has to be read against a pending reverse merger that would hand control of the listing to an anti-aging biotech and rebrand the company entirely. The corporate structure, not the legacy pipeline, is what now defines the stock.

Company and Latest Development

Pulmatrix, Inc (NASDAQ: PULM) is a clinical-stage biotechnology company historically known for its iSPERSE inhaled dry-powder platform. In recent quarters it has functioned largely as a small, cash-conserving Nasdaq-listed shell seeking a strategic combination.

On March 26, 2026, Pulmatrix announced a definitive agreement for a reverse merger with Eos SENOLYTIX. Under the terms disclosed, Eos stakeholders would own roughly 94% of the combined company on a fully diluted basis, with existing Pulmatrix shareholders retaining about 6%. The combined entity is expected to operate as Eos SENOLYTIX, Inc. and to trade on Nasdaq under the ticker "EOSX," pending exchange approval. The deal followed the termination, on March 2, 2026, of an earlier planned merger with Cullgen.

What Is Driving Attention Around PULM?

Any recent uptick in trading interest lacks a single, clearly verified public catalyst, and thin floats like Pulmatrix's can produce sharp moves on modest volume. What is verifiable is the merger itself. Eos SENOLYTIX develops gerotherapeutic peptide medicines aimed at aging-related mitochondrial dysfunction. Its lead candidate, PTC-2105, targets sarcopenia and sarcopenic obesity through a proprietary platform the company calls MitoXcel, with preclinical results the company describes as increasing lean mass without the muscle loss associated with GLP-1 weight-loss therapies. That positioning, adjacent to the enormous GLP-1 theme, is part of why the transaction has drawn interest.

Key Numbers and Company Position

The disclosed post-closing ownership split is approximately 94% Eos and 6% legacy Pulmatrix holders. Financing tied to the deal includes a $1 million Series B convertible preferred stock issuance by Pulmatrix (1,000 shares at a $1,000 stated value, 8% cumulative dividend, $2.20 conversion price) and, on the Eos side, up to $18 million via convertible notes and Equity across multiple closings, plus a planned Series A preferred financing. Precise current cash balances were not specified in the filing summary reviewed.

What Could Come Next?

The defining catalyst is completion of the merger, which was expected around mid-2026 subject to stockholder approvals and the effectiveness of an SEC registration statement. A successful close would bring the EOSX rebrand and a new clinical focus on gerotherapeutics. Investors may be watching for the closing timeline, the registration statement, and any early clinical or preclinical updates on PTC-2105.

Risks to Watch

Reverse mergers carry execution risk: deals can be delayed, repriced or terminated, as the earlier Cullgen collapse illustrates. The heavy dilution to legacy Pulmatrix holders is substantial, leaving them a minority slice. Eos's lead program is early and unproven in humans, and the financing structure implies further dilution. If the merger fails, Pulmatrix would again face the strategic and cash pressures of a small shell company.

Conclusion

For Pulmatrix, the signal is corporate rather than clinical. The announced reverse merger with Eos SENOLYTIX, the planned EOSX rebrand and the roughly 94%/6% ownership split are the developments that matter, set against a backdrop where a prior deal already fell through. Investors following PULM may want to track whether the transaction closes on schedule and how the market receives the pivot toward anti-aging peptide medicine.